Processa Pharmaceuticals Files 8-K
Ticker: PCSA · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
TL;DR
Processa Pharma filed an 8-K with financial statements and exhibits. Nothing major disclosed yet.
AI Summary
On October 2, 2024, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing serves as a public record of Processa Pharmaceuticals' financial statements and exhibits, providing transparency to investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant risk or negative developments.
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- October 2, 2024 (date) — Date of earliest event reported
- 001-39531 (other) — Commission file number
- Delaware (other) — State of incorporation
- 45-1539785 (other) — I.R.S. Employer Identification Number
- 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076 (address) — Address of Principal Executive Offices
- 443-776-3133 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Processa Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of October 2, 2024.
What is the Commission file number for Processa Pharmaceuticals, Inc.?
The Commission file number for Processa Pharmaceuticals, Inc. is 001-39531.
In which state was Processa Pharmaceuticals, Inc. incorporated?
Processa Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for Processa Pharmaceuticals, Inc.?
The principal executive office address is 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076.
What is the telephone number listed for Processa Pharmaceuticals, Inc.?
The telephone number listed for Processa Pharmaceuticals, Inc. is (443) 776-3133.
Filing Stats: 719 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-10-02 16:36:29
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-24-039220.txt ( ) — 239KB
- pcsa-20241002.xsd (EX-101.SCH) — 3KB
- pcsa-20241002_lab.xml (EX-101.LAB) — 33KB
- pcsa-20241002_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01. Other Event
Item 8.01. Other Event. On October 2, 2024, Processa Pharmaceuticals, Inc. (the "Company") issued a press release announcing the dosing of a patient in a Phase 2 clinical trial of NGC-Cap which satisfies the diligence milestone under the Company's license agreement for PCS6422 with Elion Oncology, Inc. Multiple trial sites have been established and are now recruiting patients. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference. The Company has now timely satisfied all of the Company's diligence obligations, as enumerated in Article V, in its license agreement with Elion Oncology, Inc. The Company has previously referred to the Condition Precedent Satisfaction Date for its diligence obligations as October 2, 2024, but has determined that such statements should have been October 6, 2024 which is the anniversary of the funding event that triggers the calculation of the Condition Precedent Satisfaction Date. Safe Harbor Statement Information provided in this Current Report on Form 8-K contain forward-looking statements. The statements in this Current Report on Form 8-K that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, the Company can give no assurance these expectations will be attained, and it is possible actual results may differ materially from those indicated by these forward-looking statements due to a variety of risks and uncertainties. Please refer to the documents filed by the Company with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements